The U.S. FDA is considering how to handle its National Priority Voucher (CNPV) program after its introduction last year. The provided material says the program aims to create an ultrafast review pathway for drugs and biologics of strategic national importance while maintaining regulatory standards. Since launch, FDA has reportedly welcomed 18 products from 16 companies into the priority voucher framework, with reviews positioned to take roughly one to two months instead of the standard 10 to 12. For biotech sponsors, CNPV matters because it changes the competitive calculus for development timelines, resource planning for clinical evidence packages, and how companies sequence filings for high-priority indications tied to national interests.